Yervoi 50mg Injection

Yervoi 50mg Injection contains Ipilimumab, a monoclonal antibody that improves the immune system’s ability to target and destroy cancer cells.

Brand Name: Yervoi

Composition: Ipilimumab

Mechanism of Action:

Ipilimumab inhibits the receptor known as cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), which suppresses T-cell activation. It increases T-cell activity by blocking CTLA-4, which encourages an immune-mediated assault on cancer cells.

Uses:

Melanoma

Dosage and Administration:

Intravenous infusion is the method of administration. For melanoma, 3 mg/kg is usually given every three weeks for a total of four treatments. Depending on the indication or combination therapy, different dose changes may be necessary.

Side Effects:

• Fatigue
• Diarrhea
• Skin rash
• Itching
• Vomiting
• Nausea
• Headache

Safety Advise:

Lungs  

The safety of Yervoi for individuals with lung issues is uncertain. Kindly speak with your healthcare provider.

Liver  

The safety of Yervoi for individuals with liver issues is uncertain. Kindly speak with your healthcare provider.

Kidney  

The safety of Yervoi for individuals with Kidney issues is uncertain. Kindly speak with your healthcare provider.

Pregnancy  

Yervoi should be used during pregnancy only if clearly needed, Kindly speak with your healthcare provider.

Breast Feeding  

Using Yervoi while nursing is most likely dangerous. Kindly speak with your healthcare provider. 

Storage:

Store in a refrigerator at 2°C to 8°C (36°F to 46°F). Do not freeze.

How to use this Medication?

An intravenous injection of ipilimumab is given by a physician or nurse. It is administered for ninety minutes every three weeks (four doses) and then every twelve weeks to prevent melanoma. As directed by your physician, it is administered either by alone or in combination with nivolumab for 30 minutes every three or six weeks to treat melanoma, kidney, hepatic, colorectal, or other malignancies.

You will be closely watched both during and after the infusion because ipilimumab might induce dangerous infusion reactions. Inform your doctor right once if you experience any of the following symptoms: fever, chills, rash, flushing, breathing difficulties, or dizziness.

Disclaimer:

The main goal of Apothecare Wellness is to make sure that the information it provides to customers is correct, reliable, and reviewed by specialists. This website's contents and information are strictly for informational purposes. They are not meant to be used in place of expert medical advice, diagnosis, or care. Please consult your physician for guidance and ask any questions you may have about any condition or medication. If you read anything on Apothecare Wellness, do not discount or delay obtaining competent medical advice. Our goal is to enhance the doctor-patient relationship, not to take its place.

Marketer details

Name: Bristol Myers Squibb

Address: Bristol Myers Squibb Corporate Headquarters 430 E. 29th Street, 14th Floor, New York, NY 10016

Country of origin: India